The Europe Pain Patch Market should witness market growth of 4.0% CAGR during the forecast period (2023-2029).
The market is anticipated to develop due to the rising usage of pain patches for non-cancer conditions. Rising usage of pain patches as a handy and simple-to-use practical choice, as well as the growing acceptability of non-invasive pain management techniques. Over the projected period, the demand for pain patches will be driven by the rising occurrence of traffic accidents, trauma, injuries, severe chronic illnesses, and post-surgery pain. The market's sales are boosted by the fact that pain patches are sold at retail pharmacies, online retailers, and hospital pharmacies.
In addition, with cutting-edge products and technology, several start-ups have joined the market for pain patches. In comparison to alternative administration methods, pain patches have the benefit of regulated medicine distribution due it uses a transdermal route. Throughout the projection period, this benefit might increase sales of pain patches. Moreover, alterations in lifestyle and the growth of office-related employment that require prolonged periods of time spent sitting still may cause, among other things, back-related illnesses. The market for pain patch will experience a significant growth as a result of this.
According to the Falls and Fracture Consensus Statement, which was released in January 2017 by Public Health England and member organizations of the National Falls Prevention Coordination Group, the total cost of fragility fractures in the UK has been estimated at £4.4 billion, of which £1.1 billion goes toward social care. Of this sum, roughly £2 billion is attributable to hip fractures. More than 240,000 falls in hospitals were reported in acute hospitals and mental health trusts in Wales and England, making them the most frequent patient safety-related incident. The market will surge due to the increased demand for pain management, owing to the increasing number of falls causing more pain among the older population, thereby driving the market expansion.
The Germany market dominated the Europe Pain Patch Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $413.9 million by 2029. The UK market is anticipated to grow at a CAGR of 3.1% during (2023-2029). Additionally, The France market would exhibit a CAGR of 4.8% during (2023-2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Type, the market is segmented into Prescription Medicines and OTC Medicines. Based on Product Type, the market is segmented into Non-Opioid Patches and Opioid Patches. Based on Non-Opioid Patches Type, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Methyl Salicylate, Lidocaine and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include NEXGEL, Inc. Viatris, Inc. Johnson & Johnson. Teva Pharmaceutical Industries Ltd. Grunenthal GmbH. Sorrento Therapeutics, Inc. Hisamitsu Pharmaceutical Co. Inc. Endo International PLC. Purdue Pharma L.P. Amneal Pharmaceuticals, Inc.
The market is anticipated to develop due to the rising usage of pain patches for non-cancer conditions. Rising usage of pain patches as a handy and simple-to-use practical choice, as well as the growing acceptability of non-invasive pain management techniques. Over the projected period, the demand for pain patches will be driven by the rising occurrence of traffic accidents, trauma, injuries, severe chronic illnesses, and post-surgery pain. The market's sales are boosted by the fact that pain patches are sold at retail pharmacies, online retailers, and hospital pharmacies.
In addition, with cutting-edge products and technology, several start-ups have joined the market for pain patches. In comparison to alternative administration methods, pain patches have the benefit of regulated medicine distribution due it uses a transdermal route. Throughout the projection period, this benefit might increase sales of pain patches. Moreover, alterations in lifestyle and the growth of office-related employment that require prolonged periods of time spent sitting still may cause, among other things, back-related illnesses. The market for pain patch will experience a significant growth as a result of this.
According to the Falls and Fracture Consensus Statement, which was released in January 2017 by Public Health England and member organizations of the National Falls Prevention Coordination Group, the total cost of fragility fractures in the UK has been estimated at £4.4 billion, of which £1.1 billion goes toward social care. Of this sum, roughly £2 billion is attributable to hip fractures. More than 240,000 falls in hospitals were reported in acute hospitals and mental health trusts in Wales and England, making them the most frequent patient safety-related incident. The market will surge due to the increased demand for pain management, owing to the increasing number of falls causing more pain among the older population, thereby driving the market expansion.
The Germany market dominated the Europe Pain Patch Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $413.9 million by 2029. The UK market is anticipated to grow at a CAGR of 3.1% during (2023-2029). Additionally, The France market would exhibit a CAGR of 4.8% during (2023-2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Type, the market is segmented into Prescription Medicines and OTC Medicines. Based on Product Type, the market is segmented into Non-Opioid Patches and Opioid Patches. Based on Non-Opioid Patches Type, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Methyl Salicylate, Lidocaine and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include NEXGEL, Inc. Viatris, Inc. Johnson & Johnson. Teva Pharmaceutical Industries Ltd. Grunenthal GmbH. Sorrento Therapeutics, Inc. Hisamitsu Pharmaceutical Co. Inc. Endo International PLC. Purdue Pharma L.P. Amneal Pharmaceuticals, Inc.
Scope of the Study
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Type
- Prescription Medicines
- OTC Medicines
By Product Type
- Non-Opioid Patches
- Nonsteroidal Anti-Inflammatory Drugs
- Methyl Salicylate
- Lidocaine
- Others
- Opioid Patches
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- NEXGEL, Inc.
- Viatris, Inc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Grunenthal GmbH
- Sorrento Therapeutics, Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Endo International PLC
- Purdue Pharma L.P.
- Amneal Pharmaceuticals, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Pain Patch Market, by Distribution Channel
1.4.2 Europe Pain Patch Market, by Type
1.4.3 Europe Pain Patch Market, by Product Type
1.4.4 Europe Pain Patch Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Pain Patch Market by Distribution Channel
3.1 Europe Drug Stores & Retail Pharmacies Market by Country
3.2 Europe Hospital Pharmacies Market by Country
3.3 Europe Online Providers Market by Country
Chapter 4. Europe Pain Patch Market by Type
4.1 Europe Prescription Medicines Market by Country
4.2 Europe OTC Medicines Market by Country
Chapter 5. Europe Pain Patch Market by Product Type
5.1 Europe Non-Opioid Patches Market by Country
5.2 Europe Pain Patch Market by Non-Opioid Patches Type
5.2.1 Europe Nonsteroidal Anti-Inflammatory Drugs Market by Country
5.2.2 Europe Methyl Salicylate Market by Country
5.2.3 Europe Lidocaine Market by Country
5.2.4 Europe Others Market by Country
5.3 Europe Opioid Patches Market by Country
Chapter 6. Europe Pain Patch Market by Country
6.1 Germany Pain Patch Market
6.1.1 Germany Pain Patch Market by Distribution Channel
6.1.2 Germany Pain Patch Market by Type
6.1.3 Germany Pain Patch Market by Product Type
6.1.3.1 Germany Pain Patch Market by Non-Opioid Patches Type
6.2 UK Pain Patch Market
6.2.1 UK Pain Patch Market by Distribution Channel
6.2.2 UK Pain Patch Market by Type
6.2.3 UK Pain Patch Market by Product Type
6.2.3.1 UK Pain Patch Market by Non-Opioid Patches Type
6.3 France Pain Patch Market
6.3.1 France Pain Patch Market by Distribution Channel
6.3.2 France Pain Patch Market by Type
6.3.3 France Pain Patch Market by Product Type
6.3.3.1 France Pain Patch Market by Non-Opioid Patches Type
6.4 Russia Pain Patch Market
6.4.1 Russia Pain Patch Market by Distribution Channel
6.4.2 Russia Pain Patch Market by Type
6.4.3 Russia Pain Patch Market by Product Type
6.4.3.1 Russia Pain Patch Market by Non-Opioid Patches Type
6.5 Spain Pain Patch Market
6.5.1 Spain Pain Patch Market by Distribution Channel
6.5.2 Spain Pain Patch Market by Type
6.5.3 Spain Pain Patch Market by Product Type
6.5.3.1 Spain Pain Patch Market by Non-Opioid Patches Type
6.6 Italy Pain Patch Market
6.6.1 Italy Pain Patch Market by Distribution Channel
6.6.2 Italy Pain Patch Market by Type
6.6.3 Italy Pain Patch Market by Product Type
6.6.3.1 Italy Pain Patch Market by Non-Opioid Patches Type
6.7 Rest of Europe Pain Patch Market
6.7.1 Rest of Europe Pain Patch Market by Distribution Channel
6.7.2 Rest of Europe Pain Patch Market by Type
6.7.3 Rest of Europe Pain Patch Market by Product Type
6.7.3.1 Rest of Europe Pain Patch Market by Non-Opioid Patches Type
Chapter 7. Company Profiles
7.1 NEXGEL, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.2 Viatris, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental Analysis
7.2.4 Research & Development Expense
7.3 Johnson & Johnson
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 SWOT Analysis
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Grünenthal GmbH
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trials:
7.6 Sorrento Therapeutics, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental Analysis
7.6.4 Research & Development Expenses
7.7 Hisamitsu Pharmaceutical Co. Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Recent strategies and developments:
7.7.3.1 Product Launches and Product Expansions:
7.8 Endo International PLC
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expense
7.9 Purdue Pharma L.P.
7.9.1 Company Overview
7.10. Amneal Pharmaceuticals, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations, and Agreements:
7.10.5.1 Approvals & Trials:
Companies Mentioned
- NEXGEL, Inc.
- Viatris, Inc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Grunenthal GmbH
- Sorrento Therapeutics, Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Endo International PLC
- Purdue Pharma L.P.
- Amneal Pharmaceuticals, Inc.
Methodology
LOADING...
